Dr. Agarwals Health Care Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%). H1 FY27 revenue ₹1,269 Cr (+28.7%), PAT ₹112 Cr (+50.1%). Strategy is aggressive facility expansion, with 65 FY27E additions.
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
3,013 announcements with these filters
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%). H1 FY27 revenue ₹1,269 Cr (+28.7%), PAT ₹112 Cr (+50.1%). Strategy is aggressive facility expansion, with 65 FY27E additions.
Q2 FY27 revenue +2.4% to ₹2,694mn, PAT flat at ₹562mn, EBITDA margin 39.9%; H1 PAT +8.3%. Q2 hit by Navratri shift; SSSG -5.8%.
Q2 FY27: PAT ₹7.4 Cr (+180.6% YoY), EBITDA ₹13.6 Cr at 25.6% margin; H1 PAT ₹22.5 Cr. Profit rose on deliveries and collections, while H1 bookings fell 35.1%.
Standalone revenue ₹2,019 Cr (+64%) and PAT ₹161 Cr, but group EBITA margin fell to 18.63% from 24.16%. Management raised FY27 growth to ~20% while admitting order inflow is a challenge and working capital stretched to 152 days.
Q2 FY27 consolidated revenue ₹5,921 Mn (+15% YoY), but EBITDA ₹284 Mn (−56%, 4.8% margin) and PAT ₹176 Mn (−58%). Performance Polymers & Chemicals sales +33%; Agri weak.
Q2 revenue rose 23.2% to ₹585 Cr and EBITDA margin reached 12.9% (+90bps), led by festive demand and induction cookware. Exports lagged, and borrowings rose on inventory build-up and China capex.
Q2 FY27 value-added revenue rose 32.2% on volume and content gains; PAT up 15%. Management is upbeat, but commodity cost recovery is unresolved and the export order book has softened sharply.
Q2 FY27 consolidated revenue ₹47.1cr (+50% YoY), EBITDA ₹11.3cr (+65%), PAT ₹6.6cr (+30%). Capacity utilisation 46%. Parenterals facility pending commissioning.
H1FY27 standalone revenue Rs 2,425 Mn (+6.0% YoY), EBITDA margin 10.2%, PAT Rs 172 Mn (-29.3% YoY). CRGO volumes up 28%; FY27 growth guided at 30-35%.
Q2FY27 revenue Rs1,269cr (+18%), EBITDA Rs115cr (+26%), adjusted PAT Rs46cr (+22%). H1 adjusted PAT Rs89cr (+30%). FY27 PAT guidance of Rs200-220cr reiterated.
H1 headline growth is largely timing: carried-over March orders executed in H1, with receivables high and cash conversion weak.
H1 FY27 revenue ₹528.47 Cr (+67.69%), EBITDA ₹42.37 Cr (+99.48%), PAT ₹19.08 Cr (+105%). Margin gains are real, but negative operating cash flow and working-capital strain are played down.
H1 FY27 revenue INR 13.7bn (+14% y-o-y), adj. EBITDA INR 1.8bn (13.1%), PAT INR 0.5bn. Sales fell to INR 38bn; net debt rose to INR 4.5bn. FY27 pre-sales guidance INR 100bn.
Consolidated Q2 revenue rose 31%, but H1 organic growth was only 14%. Pendra Care is loss-making and Italy tenders are delayed. FY27 revenue guidance was reaffirmed and the standalone margin band raised.
Q2 FY27 revenue ₹275.7 Cr (+14.6% YoY), but EBITDA margin fell to 19.4% from 20.3%. Management admits missing its margin target while projecting US-tariff-driven demand upside without order figures.
Record Q2 FY27 revenue of about ₹376 Cr (+28% QoQ), but gross margin fell 4ppt to 49% on West Asia raw-material costs. Management gave no numerical forward guidance; margin recovery depends on price hikes from Q3.
Q2 FY27 standalone revenue ₹895.8 Cr (-6.5% YoY), PAT ₹36.8 Cr flat, EBITDA margin down to 12.2%. Order backlog ₹12,901 Cr.
H1 FY27 revenue ₹95.21 Cr (+27.5% YoY) and PAT ₹12.03 Cr; FY27 revenue outlook raised to ₹202 Cr, but operating cash flow was negative ₹4.7 Cr on receivables stretch.
Consolidated revenue of ₹1,804 Cr (+35% QoQ) and PAT of ₹61 Cr were driven by Punjab's ramp-up. Standalone EBITDA fell 11.7% QoQ as spreads normalised, and the Q1 inventory gain did not repeat.
Q2 FY27 revenue ₹135.6 Cr (+14.0%), EBITDA ₹29.8 Cr (21.5% margin), PAT ₹15.4 Cr (+45.2%). H1 PAT ₹28.1 Cr (+53.9%). Eastern India expansion; 1,000-bed target.
Revenue rose 28% YoY to ₹1,143 Cr, but consolidated EBITDA margin fell to about 36% from 39% on freight, power and staffing costs. Management says gases-segment margin rose to 39%.
Q2 FY27 consolidated revenue Rs 2030 Cr (+2% YoY), EBITDA Rs 67 Cr (-43%, margin 3.3%), PAT loss Rs 376 Cr. Festive shift hit operating leverage.
Q2 FY27 standalone PAT ₹426.66 lakh vs ₹(314.89) lakh loss in Q2 FY26, on total income of ₹28.13 lakh. Company is pivoting to Mumbai redevelopment; no quantified guidance given.
Q2 FY27 revenue flat at INR 12,107 Mn; EBITDA margin 12.41% (-72 bps YoY); PAT INR 833 Mn (+7.8%). H1 PAT INR 1,767 Mn (+15.9%). Order book INR 1,35,464 Mn, hydro-heavy.
Q2 FY27 revenue INR795 cr (+40% YoY), EBITDA INR115 cr (14.4% margin), PAT INR65 cr (+117%). Management now guides ~25%+ FY27 revenue growth.
Q2 FY27 record revenue ₹608.31 cr (+40.02% YoY); PAT ₹23.40 cr (+4.68%); EBITDA margin 11.74% vs 15.17%. C&I now 55% of revenue.
Q2 revenue ₹361 Cr (+114.6%), PAT ₹80 Cr (+73.2%), EBITDA ₹128 Cr; debt-free after IREDA repayment. Growth is strong, but margin moderation is guided as new capex comes on stream, and module utilisation is just 68%.
Q2 FY27 consolidated revenue INR 79,682 Mn (+16.6% YoY), EBITDA INR 8,554 Mn (-16.2%), margin 10.7% (-421 bps). PAT INR 2,921 Mn. India-led growth; margins hit by raw material inflation.
Q2 FY27 revenue ₹259 Cr (-55% YoY), PAT ₹7.7 Cr (-93%). H1 FY27 revenue ₹667 Cr (-2%), PAT ₹60 Cr (-27%). Management reiterates 25% FY27 topline growth target.
Q2 FY27: total income INR 7,329mn (+26.9% YoY), PAT INR 1,108mn (+263% YoY), AUM INR 1,53,228mn (+22% YoY); GNPA eased to 3.38%.